Therefore, this study aimed to interrogate the transcriptomic diversity of T-cell priming markers across and within advanced cancer types, and to determine correlations with canonical immunotherapy markers such as PD-L1 expression, TMB and/or MSI status. Here, CD274 is linked to cancer.